Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 22

Trial Status

Recruiting2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT07063199Phase 2Recruiting
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
Immune ThrombocytopeniaTreatment
Principalinvestigator
NCT07063225Phase 2Recruiting
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
Chemotherapy-induced ThrombocytopeniaRomiplostim N01
Principalinvestigator

Research Network

Collaboration Network

2 collaborators·1 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

Chinese Academy of Medical Science and Blood Disease Hospital

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

lei zhang, MD

Chinese Academy of Medical Science and Blood Disease Hospital

Moderately Similar
19 trials

Shared therapeutic areas:

TherapeuticsPurpura, Thrombocytopenic, IdiopathicChemotherapy-induced Thrombocytopenia

Worked with same sponsors:

Henan Cancer HospitalInstitute of Hematology & Blood Diseases Hospital, China+5 more
Collaborated on 1 trial
Similarity Score34%

Liyan Miao

The First Affiliated Hospital of Soochow University

Related
7 trials

Shared therapeutic areas:

Chemotherapy-induced ThrombocytopeniaPurpura, Thrombocytopenic, Idiopathic
Similarity Score15%

Lei Zhang, MD

Institute of Hematology & Blood Diseases Hospital, China

Related
10 trials

Shared therapeutic areas:

Purpura, Thrombocytopenic, IdiopathicTherapeutics

Worked with same sponsors:

Henan Cancer HospitalInstitute of Hematology & Blood Diseases Hospital, China+2 more
Similarity Score15%

Thomas Ortel, MD

Duke University

Related
4 trials

Shared therapeutic areas:

Purpura, Thrombocytopenic, Idiopathic
Similarity Score8%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

Related
74 trials

Shared therapeutic areas:

Therapeutics

Worked with same sponsors:

Tianjin Third Central Hospital
Similarity Score8%

James Bussel, MD

Weill Medical College, Cornell University

Related
2 trials

Shared therapeutic areas:

Purpura, Thrombocytopenic, Idiopathic
Similarity Score8%

Nigel Key, MD

University of North Carolina, Chapel Hill

Related
4 trials

Shared therapeutic areas:

Purpura, Thrombocytopenic, Idiopathic
Similarity Score8%

Harlan M Krumholz, M.D., S.M.

Yale University

Related
6 trials

Shared therapeutic areas:

Therapeutics
Similarity Score8%

Charles Conway, MD

Washington University School of Medicine

Related
6 trials

Shared therapeutic areas:

Therapeutics
Similarity Score8%

Zhen Jun Wang, M.D.

Beijing Chao Yang Hospital

Related
3 trials

Shared therapeutic areas:

Therapeutics

Worked with same sponsors:

Tianjin Third Central Hospital
Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT07063199Phase 2PrincipalInvestigator

Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)

Immune ThrombocytopeniaTreatment
Recruiting
NCT07063225Phase 2PrincipalInvestigator

Romiplostim N01 for Chemotherapy-induced Thrombocytopenia

Chemotherapy-induced ThrombocytopeniaRomiplostim N01
Recruiting

All 2 trials loaded